Topics and Pearls
- Disease states such as atopic dermatitis, eczema, melanoma, psoriasis, and vitiligo
- Insights into topical and systemic therapies for skin disease
- Pearls for clinical practice management
- Pediatric dermatology and conference pearls
News
Article
Author(s):
Dermatology Times is recapping our top expert interviews from the month of July.
James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.
Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.
Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.
Shahriari spoke about the importance of comprehensive care, collaborating with other specialists, and addressing psychosocial impact.
Adewole Adamson, MD, MPP, discusses the Environmental Working Group's 2024 Guide to Sunscreens and what clinicians should discuss with patients who express concerns with the headlines stemming from the report.
Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.
Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.
Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.
In this episode, Albert Yan, MD, FAAP, FAAD, discusses his SPD 2024 session revolving around the helpful (or hindering?) role of artificial intelligence and chatbots in dermatology.
Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.
Caulfield discusses his SPD 2024 lecture, "The Misinformation Crisis: How Did We Get Here and What Can We Do?"
Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."
Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.
Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.
In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?
Smidt and Hunt offer insights on navigating pediatric dermatology decision-making, emphasizing learning from clinical scenarios and fostering a culture of feedback and improvement.
Metz and Tollefson share insights on efficient practice management, work-life balance, and exciting developments in pediatric dermatology.
David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.
Researchers behind the latest benzene studies found no increased cancer risk with use of products containing benzoyl peroxide.
Diamant Thaçi, MD, PhD, shares insights on the data presented at the World Psoriasis & Psoriatic Arthritis (IFPA) Conference.
Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.
Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.
Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.